Tailored drug dosing may cut infections after stem cell transplants
NCT ID NCT07648992
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving anti-thymocyte globulin (ATG) based on individual patient levels can reduce viral infections after stem cell transplants from unrelated donors. About 324 patients will receive either personalized or fixed doses of ATG. The goal is to find a dose that prevents graft-versus-host disease without increasing the risk of infections like CMV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-thymocyte globulin (ATG)
- What this could lead to
- If successful, this could lead to a safer, more effective way to prevent graft-versus-host disease and reduce viral infections after stem cell transplants, improving survival.
- What could go wrong
- This is a single-center study in China, and results may not apply to other populations. The approach is still being tested, and balancing infection risk with graft-versus-host disease prevention remains challenging.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can gut bacteria help rebuild immunity after stem cell transplants?
- Can a different immune drug cut viral infections after stem cell transplants?
- Can a simple blood test make a key transplant drug safer?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Could virtual reality help patients recover faster from cell therapy?
- Herbal granules aim to lift mood in transplant survivors